AR123174A1 - Agonistas del receptor npy2 solubles - Google Patents

Agonistas del receptor npy2 solubles

Info

Publication number
AR123174A1
AR123174A1 ARP210102204A ARP210102204A AR123174A1 AR 123174 A1 AR123174 A1 AR 123174A1 AR P210102204 A ARP210102204 A AR P210102204A AR P210102204 A ARP210102204 A AR P210102204A AR 123174 A1 AR123174 A1 AR 123174A1
Authority
AR
Argentina
Prior art keywords
group
gln
glu
ala
leu
Prior art date
Application number
ARP210102204A
Other languages
English (en)
Inventor
Peter Wilhelm Haebel
Albert Brennauer
Stefan Peters
Charlotte Stahl Madsen
Sren Ljungberg Pedersen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR123174A1 publication Critical patent/AR123174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Análogos de PYY que tienen alanita en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos son solubles a alrededor de pH 6 y 7. También composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos. Reivindicación 1: Un análogo de PYY, caracterizado porque el análogo de PYY es un compuesto que tiene la fórmula: R¹-Z-R², en donde R¹ es hidrógeno, -C(O)C₁₋₆ alquilo, -C(O)C₆H₆, -C(O)C₃₋₆ cicloalquilo, -C(O)C₁₋₆ alquil-C₃₋₆ cicloalquilo, C₁₋₆ alquilo o C₁₋₆ alquil-C₃₋₆ cicloalquilo; R² es OH o NHR³, en donde R³ es hidrógeno o C₁₋₃ alquilo; y Z es un péptido que comprende una secuencia de aminoácidos de la fórmula Ib: Ala-Pro-X⁶-Lys-X⁸-X⁹-X¹⁰-X¹¹-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-Gln-X¹⁹-X²⁰-X²¹-X²²-X²³-Leu-Arg-His-X²⁷-X²⁸-X²⁹-X³⁰-Leu-X³²-X³³-Gln-Arg-Tyr (Ib) en donde X⁶ se selecciona del grupo que consiste en Ala y Glu; X⁸ se selecciona del grupo que consiste en Ala y Pro; X⁹ se selecciona del grupo que consiste en Glu, Gly y Pro; X¹⁰ se selecciona del grupo que consiste en Ala y Glu; X¹¹ se selecciona del grupo que consiste en Ala, Asp, Glu, Ile, Leu, Pro, Gln y Ser; X¹² se selecciona del grupo que consiste en Ala, Glu, Leu, Pro, Gln y Ser; X¹³ se selecciona del grupo que consiste en Ala, Glu, Leu, Ser, Gln, Thr y Pro; X¹⁴ se selecciona del grupo que consiste en Ala, Glu, Leu, Pro, Gln y Ser; X¹⁵ se selecciona del grupo que consiste en Ala y Glu; X¹⁶ se selecciona del grupo que consiste en Ala, Glu y Lys; X¹⁷ se selecciona del grupo que consiste en Ala, Glu, Ile, Leu, Pro, Gln, Ser, Thr y Val; X¹⁹ se selecciona del grupo que consiste en Ala, Glu, Leu, Arg, Lys, Pro, Ser y Gln; X²⁰ se selecciona del grupo que consiste en Gln y Tyr; X²¹ se selecciona del grupo que consiste en Gln y Tyr; X²² se selecciona del grupo que consiste en Ala, Glu, Ile, Leu, Pro, Gln, Ser, Thr y Val; X²³ se selecciona del grupo que consiste en Ala, Glu, Gly, Leu, Pro, Gln, Ser, Thr y Val; X²⁷ se selecciona del grupo que consiste en Gln y Tyr; X²⁸ se selecciona del grupo que consiste en Gln y Tyr; X²⁹ se selecciona del grupo que consiste en His, Asn y Gln; X³⁰ se selecciona del grupo que consiste en Trp y Lys; X³² se selecciona del grupo que consiste en Gln, Leu, Ser y Thr; y X³³ se selecciona del grupo que consiste en Lys y Arg; en donde de uno a tres aminoácidos de X⁵, X⁶, X⁸ - X¹⁹, X²¹ - X²⁴ y X²⁶ - X³² pueden estar ausentes, y en donde un grupo de prolongación de semivida está unido al grupo épsilon amino de la lisina en la posición 7, el grupo de prolongación de semivida consiste en un sustituyente lipófilo X y un ligador U, en donde el ligador U está unido a la cadena lateral de aminoácidos y X está unido a U, y el ligador U consiste en una, dos o tres subporciones (U¹, U², U³), en donde al menos una subporción es Ahx (ácido 6-aminohexanoico).
ARP210102204A 2020-08-07 2021-08-06 Agonistas del receptor npy2 solubles AR123174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20189966 2020-08-07

Publications (1)

Publication Number Publication Date
AR123174A1 true AR123174A1 (es) 2022-11-02

Family

ID=71995807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102204A AR123174A1 (es) 2020-08-07 2021-08-06 Agonistas del receptor npy2 solubles

Country Status (19)

Country Link
US (1) US20220041678A1 (es)
EP (1) EP4192853A1 (es)
JP (1) JP2023537036A (es)
KR (1) KR20230045088A (es)
CN (1) CN116171282A (es)
AR (1) AR123174A1 (es)
AU (1) AU2021322137A1 (es)
BR (1) BR112022025623A2 (es)
CA (1) CA3185637A1 (es)
CL (1) CL2023000357A1 (es)
CO (1) CO2023000637A2 (es)
CR (1) CR20230074A (es)
DO (1) DOP2023000010A (es)
EC (1) ECSP23003649A (es)
IL (1) IL300239A (es)
MX (1) MX2023001532A (es)
PE (1) PE20231566A1 (es)
TW (1) TW202222335A (es)
WO (1) WO2022029231A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103897066A (zh) 2004-02-11 2014-07-02 安米林药品有限责任公司 具有可选择特性的杂合多肽
EP3000826A1 (en) 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
AU2007360979B2 (en) 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
AP2011005774A0 (en) 2008-12-15 2011-06-30 Zealand Pharma As Glucagon analogues.
CN102292347A (zh) 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
GEP20146056B (en) 2009-07-13 2014-03-10 Zealand Pharma As Acylated glucagon analogues
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CN102905722A (zh) 2009-11-13 2013-01-30 诺沃—诺迪斯克有限公司 长效y2受体激动剂
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
NZ604208A (en) 2010-06-24 2014-10-31 Zealand Pharma As Glucagon analogues
WO2012168431A2 (en) 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides
AP2014007797A0 (en) 2011-12-23 2014-07-31 Boehringer Ingelheim Int Glucagon analogues
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2992008B1 (en) 2013-05-02 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Therapeutic peptides
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AR098065A1 (es) 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
SI3321278T1 (sl) 2013-11-14 2019-04-30 Keybioscience Ag Mimetiki kalcitonina za zdravljenje bolezni in motenj
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2016146739A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
MX2017015105A (es) 2015-06-12 2018-05-07 Novo Nordisk As Compuestos del peptido yy (pyy) selectivos y sus usos.
EP3398961B1 (en) 2015-12-31 2022-06-29 Hanmi Pharm. Co., Ltd. Triple activator activating glucagon, glp-1 and gip receptor
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TW202208410A (zh) * 2018-11-01 2022-03-01 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CN114641303A (zh) * 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂

Also Published As

Publication number Publication date
CN116171282A (zh) 2023-05-26
BR112022025623A2 (pt) 2023-03-07
EP4192853A1 (en) 2023-06-14
JP2023537036A (ja) 2023-08-30
CR20230074A (es) 2023-04-19
MX2023001532A (es) 2023-03-08
CO2023000637A2 (es) 2023-01-26
AU2021322137A1 (en) 2023-01-19
PE20231566A1 (es) 2023-10-04
TW202222335A (zh) 2022-06-16
CA3185637A1 (en) 2022-02-10
US20220041678A1 (en) 2022-02-10
ECSP23003649A (es) 2023-03-31
IL300239A (en) 2023-03-01
WO2022029231A1 (en) 2022-02-10
DOP2023000010A (es) 2023-02-15
KR20230045088A (ko) 2023-04-04
CL2023000357A1 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
AR123174A1 (es) Agonistas del receptor npy2 solubles
JP6387008B2 (ja) インスリンアナローグダイマー
JP7126270B2 (ja) Ｎｐｒａアゴニスト、組成物およびその使用
US10471136B2 (en) Pharmaceutical composition for injection
JP2012530145A5 (es)
CZ287797A3 (cs) Lipofilní deriváty peptidových hormonů
KR20150126042A (ko) 액체 수성 조성물
ECSP22037660A (es) Agonistas del receptor npy2
MX2014015028A (es) Fragmentos o variantes de fibronectina modificada y usos de los mismos.
JP2010523501A5 (es)
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
CA3021231A1 (en) Pegylated bioactive peptides and uses thereof
ES2283799T3 (es) Peptidos vegf y su utilizacion.
JP2019520336A5 (es)
EP2911686B1 (en) Peptides for preventing ischemic tissue injury
RU2020126021A (ru) Комбинация пептидов, ингибирующих проникновение вируса SARS-COV-2 в клетку человека
BR112022006297A2 (pt) Agonistas de receptor de npy2
CA3104183A1 (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CZ6764U1 (cs) Peptldové analogy kuřecího GnRH II a lososího GnRH